Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 16Medulloblastoma 5Glioma 5Brain Neoplasms 5Neoplasms 3Recurrence 2Oligodendroglioma 2Central Nervous System Neoplasms 2Sarcoma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Gliosarcoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 1TP protocol 1Spinal Puncture 1Radiotherapy 1Lomustine 1Cetuximab 1Blood Specimen Collection 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Recurrence, Local × Lomustine × 1 year × Clear all
NCT07100730 2026-04-16

IPAX BrIGHT

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
50 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local, Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡